AbbVie

AbbVie has announced that its board of directors unanimously elected CEO Robert A. Michael to also serve as chairman, effective July 1, 2025.

The board of directors at AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share.

AbbVie and Xilio Therapeutics have entered into a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies.

Allergan Aesthetics, a company under AbbVie, is set to open three new Allergan Medical Institute (AMI) Training Centers in the United States.

The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO, a combination of aztreonam and avibactam, for treating adults with complicated intra-abdominal infections (cIAI).